Clinical trial
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205 · Stony Brook University, Other · Withdrawn
Key facts
| NCT number | NCT00296205 |
|---|---|
| Title | Phase II High-Dose Cyclophosphamide for Multiple Sclerosis |
| Official title | Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis |
| Lead sponsor | Stony Brook University, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Cyclophosphamide |
| Enrollment | 25 |
| Start date | Oct 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Feb 24, 2006 |
| Last update posted | Jul 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: